ArticleTranslational pediatrics2025
Ewing's sarcoma family of tumors in adolescents in Beijing 2010-2019: a multicenter retrospective cohort study.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ewing's sarcoma family of tumors (ESFTs) comprises a group of aggressive malignancies predominantly affecting children and adolescents. This study aimed to evaluate the clinical characteristics, treatment outcomes, and prognostic factors in adolescent patients with ESFTs. Methods: A multicenter, retrospective cohort study was conducted on adolescents (aged 10-18 years) diagnosed with ESFTs between January 2010 and December 2019 across four major pediatric hospitals in Beijing, China. Results: A total of 79 patients were included. Primary tumors originated in bone in 75.9% of cases and in soft tissue in 24.1%, with metastases present at diagnosis in 31.6% of patients. The median tumor diameter was 5.8 cm for bone lesions and 8.0 cm for soft tissue lesions. Most patients (91.1%) received multimodal treatment. The 5-year overall survival (OS) and event-free survival rates were 64.5% and 59.0%, respectively. Univariate analysis identified several factors associated with poorer survival: tumor diameter exceeding 8 cm, trunk as the primary tumor site, absence of multimodal treatment, and initiation of local therapy more than 18 weeks after diagnosis. However, multivariate analysis revealed that metastatic disease at presentation was the only independent predictor of reduced OS. Conclusions: Metastasis is a prevalent and critical prognostic factor in adolescent ESFT patients. Multimodal treatment and timely initiation of local therapy may contribute to improved survival outcomes. These findings underscore the importance of early, comprehensive treatment strategies in managing ESFTs in adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.